N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Provides a patent application update for Nuvec.
The patent application was originally filed in March 2020 for Nuvec to be used to manufacture viral vectors and to make viral vectors more efficient in applications such as ex-vivo gene therapy treatments.
Company is now making "enhancements" to the claims of the application, with a particular focus on claims of the use of the "specific spiky properties of Nuvec to load and transfect viral vectors".
Chief Executive Nigel Theobald says: "We are seeking to refine our claims to give this patent the greatest chance of being granted in a field with strong commercial opportunity. Should the patent be granted in these territories it would mirror the regions granted for the main patent which the Company has licensed from the University of Queensland and further strengthen the commercial protection of Nuvec."
The company has filed applications in Europe, the UK, the USA, Japan, India, and Canada. It intends to file applications in Australia and China soon.
Current stock price: 2.70 pence
12-month change: down 66%
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
N4 Pharma Plc (N4P)